The study is designed as a randomized, double-blind, placebo-controlled trial with an extension phase. This means that participants will be assigned by chance to receive either the study medication or placebo, and neither the participants nor the doctors will know which treatment is being given during the main part of the study. The study will involve adults between 18 and 45 years of age who have been diagnosed with Alport syndrome. Participants will need to have certain levels of kidney function and protein in their urine to take part. They will also need to be taking certain medications for their kidneys, specifically medicines known as ACE inhibitors or ARBs, which are commonly used to help protect the kidneys.

During the study, measurements will be taken to see how the treatment affects the amount of protein in the urine over time. The main focus will be on measuring the ratio of protein in the urine at specific time points during the treatment period, specifically at 16, 20, and 24 weeks. The study will also monitor participants for any unwanted effects or side effects that may occur during treatment. After the main treatment period, there will be an extension phase where participants may continue to be followed to gather more information about the long-term effects of the medication.

Participants in the study will receive Vonafexor in a fixed dose-escalation manner, meaning the dose may be gradually increased to find the most suitable level. Some participants may receive a placebo instead of the actual medication. The study will monitor the participants’ health through regular check-ups, including physical examinations and laboratory tests, to observe any changes in their condition while on the treatment and after the treatment period ends.

The trial will also measure the levels of Vonafexor in the blood to ensure they match expected concentrations. This will help researchers understand how the medication is processed in the body. The study aims to provide valuable information on the potential benefits and any side effects of Vonafexor for people with Alport syndrome.

Participants in the study will be randomly assigned to receive either Dapagliflozin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The trial will last for about 48 weeks, during which time participants will take the tablets orally and have regular check-ups to monitor their kidney function and overall health.

The main goal of the study is to determine if Dapagliflozin can prevent the worsening of kidney disease in people with Alport syndrome by reducing the amount of protein in the urine, a condition known as albuminuria. If successful, this could lead to new treatment recommendations for young people with Alport syndrome, potentially improving their quality of life by delaying the progression to more severe kidney disease. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the effects of the medication.

Participants in the study will receive Sparsentan once daily for a period of 108 weeks. During this time, researchers will monitor the safety of the medication and observe any changes in the levels of protein in the urine, which is a key indicator of kidney health. The study aims to understand how well Sparsentan works in reducing protein levels in the urine and how the body processes the medication over time.

The study will also look at how many participants experience a complete or partial remission of their kidney disease symptoms, such as a significant reduction in protein levels in the urine. Additionally, researchers will track any side effects that occur during the study, including any that might lead to stopping the treatment. This information will help determine the overall safety and potential benefits of Sparsentan for treating these specific kidney diseases in children.

Participants in the study will take the medication R3R01 orally for a period of 12 weeks. During this time, researchers will monitor the safety and tolerability of the medication by checking for any side effects and changes in health indicators such as physical exams, vital signs, and lab tests. The study will also assess how well the medication works in reducing proteinuria in patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis.

The study aims to gather information on the quality of life of participants and how it changes from the beginning to the end of the treatment. Additionally, researchers will analyze how the body absorbs and processes the medication. The study will track the number of patients who show a complete or partial response to the treatment in terms of reducing proteinuria at various points during and after the treatment period.

Participants in the study will be randomly assigned to receive either Setanaxib or a placebo. The study will be conducted over a period of 24 weeks, during which participants will take the medication orally. Throughout the study, various health checks will be performed, including monitoring heart rate, blood pressure, and kidney function. The study will also involve regular blood tests and hearing tests to ensure the safety of the participants.

The trial aims to gather information on how the body processes Setanaxib and its effects on the symptoms of Alport syndrome. By the end of the study, researchers hope to better understand the potential benefits and any side effects of Setanaxib for individuals with this condition.